Cargando…
Scintigraphic Load of Bone Disease Evaluated by DASciS Software as a Survival Predictor in Metastatic Castration-resistant Prostate Cancer Patients Candidates to 223RaCl Treatment
BACKGROUND: Aim of our study was to assess the load of bone disease at starting and during Ra-223 treatment as an overall survival (OS) predictor in metastatic castration-resistant prostate cancer (mCRPC) patients. Bone scan index (BSI) is defined as the percentage of total amount of bone metastasis...
Autores principales: | Frantellizzi, Viviana, Pani, Arianna, Ippoliti, Maria Dea, Farcomeni, Alessio, Aloise, Irvin, Colosi, Mirco, Polito, Claudia, Pani, Roberto, Vincentis, Giuseppe De |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087429/ https://www.ncbi.nlm.nih.gov/pubmed/31855572 http://dx.doi.org/10.2478/raon-2019-0058 |
Ejemplares similares
-
The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study
por: De Feo, Maria Silvia, et al.
Publicado: (2023) -
Comparing absorbed doses and radiation risk of the α-emitting bone-seekers [(223)Ra]RaCl(2) and [(224)Ra]RaCl(2)
por: Lassmann, Michael, et al.
Publicado: (2023) -
Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [(223)Ra]RaCl(2) therapy
por: Sraieb, Miriam, et al.
Publicado: (2020) -
[(223)Ra] RaCl(2) nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era
por: Yang, Yang, et al.
Publicado: (2022) -
Ultrastructural Analysis of Cancer Cells Treated with the Radiopharmaceutical Radium Dichloride ([(223)Ra]RaCl(2)): Understanding the Effect on Cell Structure
por: Diniz Filho, Joel Félix Silva, et al.
Publicado: (2023)